- Home
- AOMR vs SGMT Comparison
AOMR vs SGMT Comparison
Compare AOMR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AOMR | SGMT |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 238.7M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AOMR | SGMT |
|---|---|---|
| Price | $8.84 | $6.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $11.13 | ★ $29.75 |
| AVG Volume (30 Days) | 147.9K | ★ 533.3K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 14.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $34,705,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.56 | N/A |
| P/E Ratio | $12.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.36 | $1.73 |
| 52 Week High | $10.88 | $11.41 |
Technical Indicators
Market Signals| Indicator | AOMR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 39.50 |
| Support Level | $8.16 | $6.02 |
| Resistance Level | $8.93 | $6.55 |
| Average True Range (ATR) | 0.18 | 0.51 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 74.58 | 16.67 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.